Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters

This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.

Subjects must:

• have a dysfunctional Central Venous Access Device (CVAD) defined as unable to withdraw 3 mL blood
• have had the device in place for > 48 hours
• be clinically stable
• be 18 or older
• give informed consent